• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒药物和疫苗的最新进展

Recent Advances on Drugs and Vaccines for COVID-19.

机构信息

87803The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, China.

出版信息

Inquiry. 2021 Jan-Dec;58:469580211055630. doi: 10.1177/00469580211055630.

DOI:10.1177/00469580211055630
PMID:34818922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8673875/
Abstract

The current situation of Coronavirus Disease 2019 (COVID-19) worldwide is still very severe. Presently, many breakthroughs have been accomplished in the research and development of drugs for the treatment of COVID-19, especially vaccines; however, some of the so-called COVID-19-specific drugs highlighted in the early stage failed to achieve the expected curative effect. There is no antiviral therapy available, by stimulating protective immunity vaccine is the best choice for the future management of infection. Therefore, we aimed to identify the latest developments in the research and development of these drugs and vaccines and provide a reference for the prevention and treatment of COVID-19.

摘要

目前,全球 2019 冠状病毒病(COVID-19)的现状仍然非常严峻。目前,在治疗 COVID-19 的药物研发方面,特别是疫苗方面,已经取得了许多突破,但在早期被强调的一些所谓的 COVID-19 特效药未能达到预期的疗效。目前尚无抗病毒疗法,通过刺激保护性免疫,疫苗是未来感染管理的最佳选择。因此,我们旨在确定这些药物和疫苗研发的最新进展,为 COVID-19 的防治提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd08/8673875/94b0fafd8645/10.1177_00469580211055630-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd08/8673875/17f75e66bdc2/10.1177_00469580211055630-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd08/8673875/94b0fafd8645/10.1177_00469580211055630-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd08/8673875/17f75e66bdc2/10.1177_00469580211055630-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd08/8673875/94b0fafd8645/10.1177_00469580211055630-fig2.jpg

相似文献

1
Recent Advances on Drugs and Vaccines for COVID-19.新冠病毒药物和疫苗的最新进展
Inquiry. 2021 Jan-Dec;58:469580211055630. doi: 10.1177/00469580211055630.
2
Therapeutic Agents Against COVID-19 with Clinical Evidence.抗 COVID-19 的治疗药物:临床证据。
Curr Pharm Des. 2021;27(13):1608-1617. doi: 10.2174/1381612827666210114150951.
3
Therapeutic Development in COVID-19.新冠病毒治疗方法的研发进展
Adv Exp Med Biol. 2021;1318:435-448. doi: 10.1007/978-3-030-63761-3_25.
4
Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.治疗方法和疫苗方面的最新进展,以应对 COVID-19/SARS-CoV-2。
Hum Vaccin Immunother. 2020 Dec 1;16(12):3034-3042. doi: 10.1080/21645515.2020.1794685. Epub 2020 Aug 26.
5
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.关于在疫情爆发情况下治疗新型冠状病毒(SARS-CoV-2)的新兴治疗和预防策略的循证系统评价。
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.
6
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.预防 SARS-CoV-2 感染和治疗 COVID-19 早期阶段的药理学策略。
Int J Infect Dis. 2021 Mar;104:441-451. doi: 10.1016/j.ijid.2021.01.035. Epub 2021 Jan 18.
7
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
8
Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2.应对 COVID-19/SARS-CoV-2 的风险管理策略和治疗方式。
J Infect Public Health. 2021 Mar;14(3):331-346. doi: 10.1016/j.jiph.2020.12.023. Epub 2020 Dec 29.
9
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
10
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.

引用本文的文献

1
Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine.氯喹和羟氯喹撤稿后抗疟药作为COVID-19重新利用药物的疗效和安全性
Clin Pharmacol. 2025 Jan 16;17:1-11. doi: 10.2147/CPAA.S493750. eCollection 2025.
2
Glutamine metabolism is essential for coronavirus replication in host cells and in mice.谷氨酰胺代谢对于冠状病毒在宿主细胞和小鼠体内的复制至关重要。
J Biol Chem. 2025 Jan;301(1):108063. doi: 10.1016/j.jbc.2024.108063. Epub 2024 Dec 9.
3
Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins.

本文引用的文献

1
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.一种灭活全病毒 SARS-CoV-2 疫苗(克尔来福)的有效性和安全性:在土耳其进行的一项双盲、随机、安慰剂对照、3 期临床试验的中期结果。
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
2
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
3
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
抗病毒药物研发进展:针对关键病毒蛋白的设计策略和作用机制的综合见解。
J Microbiol Biotechnol. 2024 Jul 28;34(7):1376-1384. doi: 10.4014/jmb.2403.03008. Epub 2024 Apr 29.
4
Tracking the COVID-19 vaccines: The global landscape.追踪 COVID-19 疫苗:全球形势。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2191577. doi: 10.1080/21645515.2023.2191577. Epub 2023 Mar 30.
5
Investigating the Impacts of Information Overload on Psychological Well-being of Healthcare Professionals: Role of COVID-19 Stressor.调查信息过载对医疗保健专业人员心理健康的影响:COVID-19 应激源的作用。
Inquiry. 2022 Jan-Dec;59:469580221109677. doi: 10.1177/00469580221109677.
智利开展的灭活 SARS-CoV-2 疫苗有效性研究
N Engl J Med. 2021 Sep 2;385(10):875-884. doi: 10.1056/NEJMoa2107715. Epub 2021 Jul 7.
4
Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.SARS-CoV-2 疫苗的安全性:随机对照试验的系统评价和荟萃分析。
Infect Dis Poverty. 2021 Jul 5;10(1):94. doi: 10.1186/s40249-021-00878-5.
5
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.医护人员接种 Comirnaty(BNT162b2,辉瑞/ BioNTech)后对 Delta(B.1.617.2)和其他关注变种的中和能力,以色列。
Euro Surveill. 2021 Jul;26(26). doi: 10.2807/1560-7917.ES.2021.26.26.2100557.
6
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.新型冠状病毒疫苗 NVX-CoV2373 的安全性和有效性。
N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30.
7
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.全球报告的 SARS-CoV-2 疫苗在临床前和临床阶段的更新综述。
Int Immunopharmacol. 2021 Jul;96:107763. doi: 10.1016/j.intimp.2021.107763. Epub 2021 May 6.
8
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.苏格兰的新冠病毒德尔塔变异株:人口统计学、住院风险及疫苗有效性
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
9
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.一项关于洛匹那韦/利托那韦、洛匹那韦/利托那韦联合 IFN-β-1a 和羟氯喹对 COVID-19 住院患者疗效的开放性随机对照试验。
Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.
10
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.2 种灭活 SARS-CoV-2 疫苗对成人有症状 COVID-19 感染的效果:一项随机临床试验。
JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565.